Phase 4Not yet recruitingAge-related condition
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older
- Sponsor
- Changchun BCHT Biotechnology Co. (Industry)
- Enrolment
- 600 planned
- Conditions
- Prevention of Herpes Zoster
- Interventions
- Herpes Zoster Vaccine, Live; Placebo
- Ages
- adults, older adults
- Registry
- NCT06961721
Full record on ClinicalTrials.gov
From the registry
To evaluate the immunogenicity 42 days after vaccination with the live attenuated herpes zoster vaccine. To evaluate the safety of the live attenuated herpes zoster vaccine.
Primary outcomes
- Immunogenicity:
History
Study completion
Primary completion
Started
Registered